+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Glucagon Like Peptide 1 Agonist"

Diabetes Drug Market Outlook, 2030 - Product Thumbnail Image

Diabetes Drug Market Outlook, 2030

  • Report
  • June 2025
  • 198 Pages
  • Global
From
Incretin-based Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Thumbnail Image

Incretin-based Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • February 2025
  • 120 Pages
  • Global
From
U.S. Hormone Therapy (Retail Side) Market Size, Share & Trends Analysis Report by Product (Sex Hormones, Thyroid Hormones), by Indication, by Route of Administration (Oral, Parenteral), by Distribution Channel, and Segment Forecasts, 2025-2033 - Product Thumbnail Image

U.S. Hormone Therapy (Retail Side) Market Size, Share & Trends Analysis Report by Product (Sex Hormones, Thyroid Hormones), by Indication, by Route of Administration (Oral, Parenteral), by Distribution Channel, and Segment Forecasts, 2025-2033

  • Report
  • August 2025
  • 100 Pages
  • United States
From
United States Semaglutide Market Report by Product, Application, Distribution Channel, States and Company Analysis, 2025-2033 - Product Thumbnail Image

United States Semaglutide Market Report by Product, Application, Distribution Channel, States and Company Analysis, 2025-2033

  • Report
  • August 2025
  • 200 Pages
  • United States
From
United States Glucagon-like Peptide-1 (GLP-1) Agonists Market Report and Forecast 2025-2034 - Product Thumbnail Image

United States Glucagon-like Peptide-1 (GLP-1) Agonists Market Report and Forecast 2025-2034

  • Report
  • June 2025
  • 250 Pages
  • United States
From
Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market Report and Forecast 2025-2034 - Product Thumbnail Image

Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market Report and Forecast 2025-2034

  • Report
  • June 2025
  • 300 Pages
  • Europe
From
Middle East Diabetes Devices and Therapeutics Market Investment Opportunities - Q2 2025 Update - Product Thumbnail Image

Middle East Diabetes Devices and Therapeutics Market Investment Opportunities - Q2 2025 Update

  • Report
  • March 2025
  • 260 Pages
  • Middle East
From
Africa Diabetes Devices and Therapeutics Market Investment Opportunities - Q2 2025 Update - Product Thumbnail Image

Africa Diabetes Devices and Therapeutics Market Investment Opportunities - Q2 2025 Update

  • Report
  • March 2025
  • 260 Pages
  • Africa
From
Latin America Diabetes Devices and Therapeutics Market Investment Opportunities - Q2 2025 Update - Product Thumbnail Image

Latin America Diabetes Devices and Therapeutics Market Investment Opportunities - Q2 2025 Update

  • Report
  • March 2025
  • 210 Pages
  • Latin America
From
Asia-Pacific Diabetes Devices and Therapeutics Market Investment Opportunities - Q2 2025 Update - Product Thumbnail Image

Asia-Pacific Diabetes Devices and Therapeutics Market Investment Opportunities - Q2 2025 Update

  • Report
  • March 2025
  • 840 Pages
  • Asia Pacific
From
Europe Diabetes Devices and Therapeutics Market Investment Opportunities - Q2 2025 Update - Product Thumbnail Image

Europe Diabetes Devices and Therapeutics Market Investment Opportunities - Q2 2025 Update

  • Report
  • March 2025
  • 980 Pages
  • Europe
From
GCC Glp 1 Agonists Weight Loss Drugs Market Report: Size, Share, Growth Drivers, Trends, Opportunities & Forecast 2025-2030 - Product Thumbnail Image

GCC Glp 1 Agonists Weight Loss Drugs Market Report: Size, Share, Growth Drivers, Trends, Opportunities & Forecast 2025-2030

  • Report
  • October 2025
  • 86 Pages
  • Middle East
From
Middle East and Africa Diabetes Drug Market Outlook, 2030 - Product Thumbnail Image

Middle East and Africa Diabetes Drug Market Outlook, 2030

  • Report
  • June 2025
  • 81 Pages
  • Africa, Middle East
From
Asia-Pacific Diabetes Drug Market Outlook, 2030 - Product Thumbnail Image

Asia-Pacific Diabetes Drug Market Outlook, 2030

  • Report
  • June 2025
  • 97 Pages
  • Asia Pacific
From
Europe Diabetes Drug Market Outlook, 2030 - Product Thumbnail Image

Europe Diabetes Drug Market Outlook, 2030

  • Report
  • June 2025
  • 100 Pages
  • Europe
From
North America Diabetes Drug Market Outlook, 2030 - Product Thumbnail Image

North America Diabetes Drug Market Outlook, 2030

  • Report
  • June 2025
  • 89 Pages
  • North America
From
Global Glucagon-like Peptide 1 (GLP-1) Market (by Product, Route of Administration, & Region): Insights and Forecast with Potential Impact of COVID-19 (2022-2027) - Product Thumbnail Image

Global Glucagon-like Peptide 1 (GLP-1) Market (by Product, Route of Administration, & Region): Insights and Forecast with Potential Impact of COVID-19 (2022-2027)

  • Report
  • November 2023
  • 127 Pages
  • Global
From
Glucagon-like Peptide 1 (GLP-1) Market: Analysis By Product (Trulicity, Ozempic, Victoza, Rybelsus and Other GLP 1 Products), By Route of Administration (Injectable and Oral Medication), By Region Size and Trends with Impact of COVID-19 and Forecast up to 2027 - Product Thumbnail Image

Glucagon-like Peptide 1 (GLP-1) Market: Analysis By Product (Trulicity, Ozempic, Victoza, Rybelsus and Other GLP 1 Products), By Route of Administration (Injectable and Oral Medication), By Region Size and Trends with Impact of COVID-19 and Forecast up to 2027

  • Report
  • January 2023
  • 127 Pages
  • Global
From
Type 2 Diabetes Treatment: Global Market Outlook - Product Thumbnail Image

Type 2 Diabetes Treatment: Global Market Outlook

  • Report
  • December 2022
  • 66 Pages
  • Global
From
Latest Development, Product Innovations and Treatments for Diabetes - Product Thumbnail Image

Latest Development, Product Innovations and Treatments for Diabetes

  • Report
  • February 2020
  • 237 Pages
  • Global
From
Loading Indicator

The Glucagon Like Peptide 1 Agonist (GLP-1) market is a subset of the larger diabetes drugs market. GLP-1 agonists are a class of drugs used to treat type 2 diabetes, and are designed to mimic the effects of the hormone glucagon-like peptide-1 (GLP-1). GLP-1 agonists work by stimulating the release of insulin, reducing the amount of glucose in the blood, and slowing the rate of gastric emptying. GLP-1 agonists are typically administered via injection, and are used in combination with other diabetes medications. The GLP-1 agonist market is highly competitive, with a number of major pharmaceutical companies offering products. These include Novo Nordisk, Eli Lilly, Sanofi, AstraZeneca, and Boehringer Ingelheim. Show Less Read more